MXPA03006484A - Derivados de imidazolilo como inhibidores del factor de liberacion de corticotropina. - Google Patents

Derivados de imidazolilo como inhibidores del factor de liberacion de corticotropina.

Info

Publication number
MXPA03006484A
MXPA03006484A MXPA03006484A MXPA03006484A MXPA03006484A MX PA03006484 A MXPA03006484 A MX PA03006484A MX PA03006484 A MXPA03006484 A MX PA03006484A MX PA03006484 A MXPA03006484 A MX PA03006484A MX PA03006484 A MXPA03006484 A MX PA03006484A
Authority
MX
Mexico
Prior art keywords
releasing factor
factor inhibitors
corticotropin releasing
imidazolyl derivatives
imidazolyl
Prior art date
Application number
MXPA03006484A
Other languages
English (en)
Inventor
M Dubowchik Gene
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03006484A publication Critical patent/MXPA03006484A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
MXPA03006484A 2001-01-26 2002-01-11 Derivados de imidazolilo como inhibidores del factor de liberacion de corticotropina. MXPA03006484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26457001P 2001-01-26 2001-01-26
PCT/US2002/000841 WO2002058704A1 (en) 2001-01-26 2002-01-11 Imidazolyl derivatives as corticotropin releasing factor inhibitors

Publications (1)

Publication Number Publication Date
MXPA03006484A true MXPA03006484A (es) 2003-09-22

Family

ID=23006646

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006484A MXPA03006484A (es) 2001-01-26 2002-01-11 Derivados de imidazolilo como inhibidores del factor de liberacion de corticotropina.

Country Status (22)

Country Link
US (5) US6888004B2 (es)
EP (1) EP1359916A4 (es)
JP (1) JP2004531475A (es)
KR (1) KR20040034594A (es)
CN (1) CN1499972A (es)
BG (1) BG107999A (es)
BR (1) BR0206698A (es)
CA (1) CA2434558A1 (es)
CZ (1) CZ20032044A3 (es)
EE (1) EE200300342A (es)
HR (1) HRP20030675A2 (es)
HU (1) HUP0303721A2 (es)
IL (1) IL156813A0 (es)
IS (1) IS6889A (es)
MX (1) MXPA03006484A (es)
NO (1) NO20033350L (es)
PE (1) PE20020844A1 (es)
PL (1) PL368555A1 (es)
RU (1) RU2003126188A (es)
SK (1) SK9222003A3 (es)
WO (1) WO2002058704A1 (es)
ZA (1) ZA200305531B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156813A0 (en) * 2001-01-26 2004-02-08 Bristol Myers Squibb Co Imidazolyl derivatives and pharmaceutical compositions containing the same
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
EP1389618B1 (en) 2001-04-27 2011-06-15 Eisai R&D Management Co., Ltd. Pyrazolo 1,5-a pyridines and medicines containing the same
AU2003275589B2 (en) 2002-10-22 2009-05-28 Eisai R & D Management Co., Ltd. 7-phenyl pyrazolopyridine compounds
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
WO2006065793A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
US7815905B2 (en) * 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
EP2522351B1 (en) 2007-06-13 2017-09-06 Research Development Foundation Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
JP5485164B2 (ja) * 2007-11-29 2014-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−カルボン酸アミドの誘導体
CA2721670C (en) 2008-04-15 2013-09-10 Eisai R&D Management Co., Ltd. 3-phenylpyrazolo[5,1-b]thiazole compound
US7994203B2 (en) * 2008-08-06 2011-08-09 Novartis Ag Organic compounds
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
AR080055A1 (es) * 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
EP2688889B1 (en) * 2011-03-25 2016-05-18 Basf Se 4h-imidazo[1,2-a]imidazoles for electronic applications
US9806270B2 (en) 2011-03-25 2017-10-31 Udc Ireland Limited 4H-imidazo[1,2-a]imidazoles for electronic applications
US9502664B2 (en) 2011-11-10 2016-11-22 Udc Ireland Limited 4H-imidazo[1,2-a]imidazoles for electronic applications
US20150011772A1 (en) 2012-02-07 2015-01-08 Bayer Intellectual Property Gmbh Method for producing substituted anthranilic acid derivatives
EP2855415A4 (en) 2012-05-25 2016-05-18 Nutech Ventures Inc AMPHIPHILE CYCLOBUTENE AND CYCLOBUTANE
CN107353289A (zh) 2012-07-10 2017-11-17 Udc 爱尔兰有限责任公司 用于电子应用的苯并咪唑并[1,2‑a]苯并咪唑衍生物
AU2013292529A1 (en) * 2012-07-18 2015-02-12 Marvin J. Miller 5,5-heteroaromatic anti-infective compounds
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
CN105384691B (zh) * 2015-10-26 2018-06-29 深圳大学 一种谷氨酰胺酰基环化酶抑制剂的制备方法及应用
US11214550B2 (en) 2017-07-24 2022-01-04 University Of South Florida Bis-cyclic guanidines as antibacterial agents
WO2019169113A1 (en) * 2018-03-02 2019-09-06 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865836A (en) * 1972-12-08 1975-02-11 Janssen Pharmaceutica Nv Bicyclic imidazoles
DE2827617A1 (de) * 1978-06-23 1980-01-10 Boehringer Sohn Ingelheim Neue imidazo eckige klammer auf 1,2- alpha eckige klammer zu imidazole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
IL69417A (en) * 1982-08-27 1987-12-20 Roussel Uclaf 2-acyl imidazo(1,2-a)pyrimidines,their preparation and pharmaceutical compositions containing them
US4551530A (en) * 1984-11-19 1985-11-05 American Cyanamid Company Pyridyl imidazo[1,2-a]pyrimidines
DK155524C (da) * 1987-03-18 1989-09-11 Ferrosan As Kondenserede imidazolderivater og farmaceutiske praeparater indeholdende disse
JPH05107705A (ja) * 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
ES2126636T3 (es) * 1992-05-19 1999-04-01 Adir Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
FR2722501B1 (fr) * 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
DE69628804T2 (de) 1995-12-08 2003-12-18 Pfizer Inc., New York Substitutierte heterozyclische Derivate als CRF Antagonisten
NZ330119A (en) * 1996-02-07 2000-02-28 Janssen Pharmaceutica Nv Pyrazolopyrimidines as crf receptor antagonists
US6022978A (en) 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
EP0970958A1 (en) * 1996-10-03 2000-01-12 Nissan Chemical Industries, Limited Heterocycle-fused pyrimidinone derivatives and herbicides
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
BR9810508A (pt) 1997-07-03 2000-09-05 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento de uma desordem
EP0937081A1 (en) 1997-08-22 1999-08-25 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO 4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
BR9803368A (pt) 1997-09-05 2001-04-24 Sumitomo Chemical Co Derivados de perimidona e herbecidas contendo os mesmos
EP1044002A4 (en) * 1997-11-07 2003-05-02 Univ Johns Hopkins METHODS FOR THE TREATMENT OF HEART CONTRACTILITY
CA2300479A1 (en) * 1997-12-26 1999-07-08 Shuichi Furuya Nitrogen-containing heterocyclic compounds, their production and use
US6509338B1 (en) 1998-06-22 2003-01-21 Bristol-Myers Squibb Company Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6414161B1 (en) * 2000-08-09 2002-07-02 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis of (R)-3-(4-Bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-a]imidazol-2-one
US6696441B1 (en) * 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
HUP0303038A2 (hu) * 2000-09-21 2003-12-29 Bristol-Myers Squibb Co. Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL156813A0 (en) * 2001-01-26 2004-02-08 Bristol Myers Squibb Co Imidazolyl derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
EE200300342A (et) 2003-12-15
IS6889A (is) 2003-07-24
NO20033350L (no) 2003-09-22
WO2002058704A1 (en) 2002-08-01
PL368555A1 (en) 2005-04-04
US20040225130A1 (en) 2004-11-11
US7125990B2 (en) 2006-10-24
US6888004B2 (en) 2005-05-03
US7238699B2 (en) 2007-07-03
US20040254382A1 (en) 2004-12-16
ZA200305531B (en) 2004-07-27
HUP0303721A2 (hu) 2004-03-01
JP2004531475A (ja) 2004-10-14
CZ20032044A3 (cs) 2003-12-17
US20020183375A1 (en) 2002-12-05
CA2434558A1 (en) 2002-08-01
EP1359916A1 (en) 2003-11-12
IL156813A0 (en) 2004-02-08
SK9222003A3 (en) 2004-05-04
US7211669B2 (en) 2007-05-01
PE20020844A1 (es) 2002-09-27
US20040235924A1 (en) 2004-11-25
US20040225001A1 (en) 2004-11-11
CN1499972A (zh) 2004-05-26
HRP20030675A2 (en) 2004-08-31
RU2003126188A (ru) 2005-03-27
EP1359916A4 (en) 2004-04-07
BG107999A (en) 2004-08-31
NO20033350D0 (no) 2003-07-25
US7244746B2 (en) 2007-07-17
KR20040034594A (ko) 2004-04-28
BR0206698A (pt) 2004-04-20

Similar Documents

Publication Publication Date Title
MXPA03006484A (es) Derivados de imidazolilo como inhibidores del factor de liberacion de corticotropina.
HK1146646A1 (en) Imidazole derivatives
EG23424A (en) Fungicidal azo-carboxamide derivatives.
MXPA03000939A (es) Derivados de imidazol.
MXPA03009847A (es) Inhibidores de cinasa derivados de pirazol.
AU2003292429A8 (en) Pyrazole compounds
MXPA03002297A (es) Compuestos de triazol utiles como inhibidores de proteina cinasa.
PL377778A1 (pl) Pochodne pirazolu
MXPA03005609A (es) Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03009647A (es) Heterociclildicarbamidas como inhibidores de caspasa.
MXPA03008140A (es) Amidas de acido benzofuran-2-carboxilico sustituidas.
IL172821A0 (en) Imidazole derivatives iii
ZA200205301B (en) New imidazole derivatives.
MXPA03008394A (es) Derivados de biuretano.
AU2002354575A1 (en) Tetrahydropurinones as corticotropin releasing factor
IL159889A0 (en) Fungicidal 1-benzoxepin derivatives
GB0302231D0 (en) The pathfinder locator
GB0127426D0 (en) Pyrazole derivatives
GB0108999D0 (en) Pyrazole derivatives
ZA200301704B (en) Triazole compounds useful as protein kinase inhibitors.
GB0101135D0 (en) Inhibitors
GB0101134D0 (en) Inhibitors
GB0128453D0 (en) Inhibitors
AU2002228188A1 (en) Pyrazoles as tgf inhibitors
ZA200306119B (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors.